Latest studies
- RecruitingPHASE3
Global Trial in APG2575 for Patients With CLL/SLL
This study is looking into a new treatment called lisaftoclax for people with a type of blood cancer called CLL/SLL. It compares adding lisaftoclax to an existing BTK inhibitor treatment versus just using the BTK inhibitor alone, for patients who have already been on BTK inhibitors.
CLL/SLLCanada - RecruitingPHASE3
A Gaucher Disease Gene Therapy Trial With FLT201
This study is testing a new gene therapy called FLT201 for adults with Gaucher disease type 1. It aims to see if patients can stop their current treatment after receiving FLT201 while remaining well. This is the final stage of testing before it might become available.
Gaucher Disease Type 1Canada - RecruitingPHASE2
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
This study is looking into a new drug, AZD8965, for people with Idiopathic Pulmonary Fibrosis (IPF). It aims to see if different doses of this drug are safe and effective, compared to a dummy drug, for people with IPF, including those already on other treatments.
Idiopathic Pulmonary Fibrosis (IPF)Canada - RecruitingPHASE2
Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
This study is testing a new medicine, AHB-137, for people with long-term hepatitis B. It aims to see how well it works and if it's safe when added to their current treatment. It's for adults already taking medicine for hepatitis B.
Hepatitis B, ChronicCanada - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
This study looks at the long-term safety of a treatment called astegolimab for people with a lung condition called COPD. It's for people who have already taken part in previous studies of this drug.
Chronic Obstructive Pulmonary DiseaseCanada - Active not recruitingPHASE3
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
This study is looking into the long-term effects and safety of a medicine called mirikizumab for people with Crohn's disease. Participants have already taken part in a related study, and this new study will help us understand how the medicine works over a longer period.
Crohn's DiseaseCanada - RecruitingPHASE3
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
This study is testing a drug called pridopidine for people with Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neurone Disease. We want to see if pridopidine can slow down how ALS progresses and if it's safe to use. Participants will take the drug or a dummy pill daily.
Amyotrophic Lateral SclerosisCanada - RecruitingPHASE2, PHASE3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
This study is testing a new medicine, CSL300, for adults with advanced kidney disease on dialysis. It aims to see if CSL300 can improve heart health and is safe, especially for those with existing heart conditions or diabetes.
End Stage Kidney DiseaseCanada - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseCanada - Active not recruitingPHASE3
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
This study looks at a new medicine called risankizumab for Crohn's disease. We're checking how well it works and if it's safe for people who have already started treatment. It's like a follow-up to see how different doses work and how people feel over time.
Crohn's DiseaseCanada - Active not recruitingPHASE2, PHASE3
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
This study looks at a new medicine called guselkumab for adults with moderately to severely active Crohn's disease. Researchers want to see how well it works and if it's safe compared to other treatments or a dummy medicine.
Crohn's DiseaseCanada - RecruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
This study is testing a new drug, rilvegostomig, against a standard treatment, pembrolizumab, for advanced lung cancer. It's for people whose cancer has spread and has high levels of a specific marker called PD-L1. The aim is to see which treatment works better and is safer.
Carcinoma, Non-Small Cell LungCanada - RecruitingPHASE3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
This study is for people with advanced bowel cancer that has spread and has a specific gene change called KRAS p.G12C. It compares a new combination of treatments to standard treatment to see if it can better stop the cancer from growing.
Metastatic Colorectal CancerCanada - RecruitingPHASE2
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
This study is testing a new medicine, SAT-3247, for boys aged 7-9 with Duchenne muscular dystrophy. We want to find the best dose, see if it's safe, and check if it helps. Some boys will get the real medicine, others a dummy medicine.
Duchenne Muscular DystrophyDuchenneDMDNeuromuscular DiseasesCanada - RecruitingPHASE2, PHASE3
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
This study is testing a new medicine, icotrokinra, for people in the UK with moderately to severely active Crohn's disease. Researchers want to see if it helps reduce symptoms and if it's safe to use, compared to a dummy medicine.
Crohn DiseaseCanada - RecruitingPHASE3
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
This study looks at new drug combinations for advanced breast cancer. It compares saruparib and camizestrant with common existing treatments to see which works best for people with specific genetic changes (BRCA1, BRCA2, or PALB2m) in their cancer.
Advanced Breast CancerCanada - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
CancerCanada - Active not recruitingPHASE3
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
This study compares two treatments, risankizumab and ustekinumab, for adults with moderate to severe Crohn's disease. Researchers want to see which treatment works best to reduce Crohn's symptoms. Both treatments are given initially by IV, then by injection.
Crohn's Disease (CD)Canada - RecruitingPHASE3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This study is testing a new drug, Telisotuzumab Vedotin, against a standard treatment, Docetaxel, for advanced non-small cell lung cancer. It aims to see if the new drug works better and is safe for adults who have already had treatment.
Non Small Cell Lung CancerCanada - Active not recruitingPHASE3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
This study looks at a new medicine called upadacitinib for adults with Crohn's disease. It checks how well it works and if it's safe over a long time for people who have already started treatment in previous studies. The aim is to see if it can help manage Crohn's.
Crohn's DiseaseCanada - Active not recruitingPHASE3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called lutikizumab for people aged 12 and over with moderate to severe hidradenitis suppurativa (HS). It compares the new medicine to a dummy treatment (placebo) to see if it helps reduce HS symptoms and is safe.
Hidradenitis SuppurativaCanada - Active not recruitingPHASE3
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
This study compares a new medicine, upadacitinib, with a sugar pill (placebo) and an existing medicine, adalimumab, for adults with rheumatoid arthritis. It looks at how well these treatments work and if they are safe when methotrexate isn't enough on its own.
Rheumatoid ArthritisCanada - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
This study looks at the long-term effects and safety of a drug called mirikizumab for people with moderate to severe ulcerative colitis. It can last up to three years, with a chance to continue treatment afterward.
Ulcerative ColitisCanada - Active not recruitingNA
Implementing a Multimodal RCT Intervention to Improve the Transition of Patients With Crohn's Disease From Pediatric to Adult Care
This study looks at a new support program for young people with Crohn's or ulcerative colitis who are moving from children's to adult healthcare. It aims to make this move smoother and improve their health and well-being.
Inflammatory Bowel DiseasesCrohn DiseaseUlcerative ColitisAdolescent DevelopmentCanada - Active not recruitingPHASE3
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
This study is looking at a new treatment called Tarlatamab for advanced small cell lung cancer that has come back after earlier treatment. We want to see if Tarlatamab helps people live longer compared to standard chemotherapy.
Small Cell Lung Cancer (SCLC)Canada - Active not recruitingPHASE3
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
This study is looking at a new medicine called romosozumab for children and teenagers aged 5-17 with Osteogenesis Imperfecta (brittle bone disease). It wants to see if romosozumab is better than existing bisphosphonate medicines at preventing broken bones and improving bone strength over 12 months.
Osteogenesis ImperfectaCanada - RecruitingPHASE3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
This study looks at a new combination treatment, Sigvotatug Vedotin plus pembrolizumab, for a type of lung cancer where a protein called PD-L1 is high. We want to see if this combination works better than pembrolizumab alone to help patients.
Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungCarcinoma, Non-Small-Cell Lung (NSCLC)Canada - Active not recruitingPHASE3
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
This study looks at a new drug, apalutamide, combined with standard hormone therapy for men with high-risk prostate cancer before and after surgery. It aims to see if this combination helps shrink the cancer more and prevents it from spreading, compared to hormone therapy alone.
Prostatic NeoplasmsCanada - Enrolling by invitationPHASE2
Extension Study of Infigratinib in Children With Achondroplasia (ACH)
This study looks at a medicine called Infigratinib for children and teenagers aged 3-18 with achondroplasia, a type of dwarfism. It's an ongoing study to check the medicine's safety, how well it works, and its long-term effects on growth and quality of life.
AchondroplasiaCanada - Active not recruitingPHASE1, PHASE2
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
This study looks at new drug combinations for advanced bladder cancer. Doctors want to see if adding different medicines to pembrolizumab and enfortumab vedotin (EV) works better and is safe. The goal is to find new, effective treatments for patients.
Metastatic Urothelial CarcinomaUrothelial NeoplasmsCanada - RecruitingPHASE1
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
This study is testing a new medicine, JNJ-88549968, for people with specific types of blood cancers called myeloproliferative neoplasms (MPNs) that have a CALR gene mutation. It aims to find the safest dose and see how well it works, sometimes given with other existing treatments.
NeoplasmsCanada - RecruitingPHASE3
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is testing a new drug, linvoseltamab, for multiple myeloma that has returned or needs re-treatment. It compares linvoseltamab to a standard three-drug combination (elotuzumab, pomalidomide, and dexamethasone) to see which works better and has fewer side effects.
Relapsed Refractory Multiple Myeloma (RRMM)Canada - Active not recruitingPHASE3
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
This study looks at a new treatment called 177Lu-PSMA-617 for men with advanced prostate cancer that has spread. It compares this new treatment alongside standard care to standard care alone, aiming to see if it helps patients live longer without their cancer getting worse.
Prostatic NeoplasmsCanada - RecruitingPHASE3
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
This study is looking at a new combination of medicines, ficlatuzumab and cetuximab, for people with head and neck cancer that has come back or spread, and tested negative for HPV. It aims to see if this new combination works better than cetuximab alone.
Metastatic Head-and-neck Squamous-cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaCanada - Active not recruitingPHASE3
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
This study looks at a new long-term treatment called donidalorsen for Hereditary Angioedema (HAE). Researchers want to see if it's safe, helps reduce HAE attacks, and improves quality of life for people with this condition over time.
Hereditary AngioedemaCanada - Active not recruitingPHASE3
Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
This study looks at a new inhaled medicine, molgramostim, for a rare lung condition called autoimmune pulmonary alveolar proteinosis (aPAP). We want to see if it helps patients better than a dummy treatment. After 48 weeks, everyone gets the active medicine.
Autoimmune Pulmonary Alveolar ProteinosisCanada - RecruitingPHASE3
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
This study looks at a new drug called Tralokinumab for children and babies with moderate to severe eczema. We want to see if it's safe and helps when given with standard eczema creams. It could offer new hope for managing this condition.
Atopic DermatitisCanada - Active not recruitingPHASE3
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
This study looks at a new personalised treatment, Intismeran Autogene, combined with Pembrolizumab for high-risk melanoma. It aims to see if this combination can stop cancer from coming back better than Pembrolizumab alone after surgery, focusing on safety and effectiveness.
MelanomaCanada - Active not recruitingPHASE3
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
This study is testing new drug combinations for a type of kidney cancer called Papillary Renal Cell Carcinoma (PRCC). It compares a mix of savolitinib and durvalumab, or just durvalumab, against a standard treatment, sunitinib, for advanced PRCC linked to a specific genetic change.
Papillary Renal Cell CarcinomaCanada - Active not recruiting
Micra Transcatheter Pacing System Post-Approval Registry
This study is looking at how a tiny pacemaker, the Micra Transcatheter Pacing System, works in everyday life after it's been approved. It's for people who need this type of pacemaker due to a slow heart rate (bradycardia) to check its safety and how well it works over time.
BradycardiaCanada - Active not recruitingPHASE1
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
This study is looking into a new medicine, ABBV-101, for blood cancers called non-Hodgkin's lymphoma (NHL). It will check how safe the medicine is, how it moves through the body, and if it helps people with different types of NHL that have come back or not responded to other treatments.
Hematologic CancerCanada - RecruitingPHASE2, PHASE3
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
This study keeps an eye on people who have had a special treatment called gene-modified T-cell therapy for cancer. It aims to check their health and how well the treatment worked over a long time, making sure it's safe and effective.
NeoplasmsCanada - Active not recruitingPHASE2
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
This study is testing a new drug called batoclimab for adults with a nerve condition called Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It aims to see how well it works and if it's safe compared to a dummy drug.
Chronic Inflammatory Demyelinating PolyneuropathyCanada - Active not recruitingPHASE3
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
This study is testing a new combination treatment for a type of bladder cancer that hasn't spread deep into the bladder wall. It's comparing a new drug called Durvalumab with the standard treatment to see if it's more effective and safe.
Non-muscle-invasive Bladder CancerCanada - RecruitingPHASE3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
This study is testing a new medicine, efruxifermin, for people with a serious liver condition called NASH/MASH cirrhosis. It's to see if the medicine helps improve liver health in those with scarring that hasn't yet caused severe problems.
NASH - Nonalcoholic SteatohepatitisMASH - Metabolic Dysfunction-Associated SteatohepatitisCanada - RecruitingPHASE3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
This study is testing a new medicine, Opevesostat, for men with prostate cancer that has spread and is resistant to hormone treatment. We want to see if Opevesostat helps men live longer compared to standard hormone therapies, especially after they've had other treatments.
Prostate Cancer MetastaticCanada - RecruitingPHASE3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
This study compares a new medicine, deucravacitinib, with an existing one, ustekinumab, for long-term safety in people with moderate to severe plaque psoriasis. It focuses on participants who also have heart disease risk factors.
Plaque PsoriasisCanada - Active not recruitingPHASE3
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
This study looks at a new drug, tucatinib, combined with T-DM1 to treat advanced HER2-positive breast cancer. It aims to see if this combination works better than T-DM1 alone for cancer that has spread or can't be removed by surgery.
HER2-positive Breast CancerCanada - Active not recruitingPHASE2
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
This study is testing a new cancer medicine called tisotumab vedotin for different solid tumours, including bowel, lung, pancreas, and head and neck cancers. It's looking to see how well it works alone or with other treatments, and what side effects might happen. The study has now moved into a longer-term phase.
Colorectal NeoplasmsCarcinoma, Non-Small-Cell LungExocrine Pancreatic CancerCarcinoma, Squamous Cell of Head and NeckCanada - RecruitingPHASE3
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
This study is testing a new medicine called Afimkibart for people with moderately to severely active Crohn's disease. It's a Phase 3 study, which means it's a big step before the medicine might become widely available, looking at how well it works and if it's safe.
Moderately to Severely Active Crohns DiseaseCanada